Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menactra®
Polysaccharide Diphtheria Conjugate Vaccine · 1 trial · 2 indications
Groups 1 and 2 received booster vaccination; Groups 3 and 4 received primary vaccination. Serum bactericidal activity for the Menactra® meningococcal serogroups A, C, Y, and W-135 were at pre-vaccination for all Groups, and at 7 days (Groups 1 and 3), and 14 days (Groups 2 and 4) post-vaccination.
| Arm | Type | Description |
|---|---|---|
| Menactra® Group 1 | EXPERIMENTAL | Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination. |
| Menactra® Group 2 | EXPERIMENTAL | Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination. |
| Meningococcal Vaccine-naïve Group 3 | EXPERIMENTAL | Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination. |
| Meningococcal Vaccine-naïve Group 4 | EXPERIMENTAL | Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination. |
| Name | Type | Description |
|---|---|---|
| Polysaccharide Diphtheria Conjugate Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Subject is healthy, as determined by medical history. * Subject is between the ages of 7 and 15 years (not yet 16 years). * For subjects who participated in Study 603-02, subject previously received one dose of Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine. * The date of ...
The Polysaccharide Diphtheria Conjugate Vaccine is being developed for the prevention of meningitis. It is a vaccine candidate studied in children and is intended to protect against meningococcal infection. Sanofi is developing the vaccine, which has been evaluated in a Phase 2 clinical trial.
Sanofi develops the Polysaccharide Diphtheria Conjugate Vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is the sponsor of the clinical program evaluating this meningococcal vaccine candidate.
The Polysaccharide Diphtheria Conjugate Vaccine is in Phase 2 development. It is an investigational vaccine and is not approved. One Phase 2 trial has been completed, and no trials are currently active.
The Polysaccharide Diphtheria Conjugate Vaccine has been studied in one completed Phase 2 trial, NCT00258856. The trial enrolled 234 children aged 7 to 15 years in the United States and examined antibody persistence in children who previously received one dose of Menactra or Menomune.
Menactra is a brand name associated with the Polysaccharide Diphtheria Conjugate Vaccine. The completed Phase 2 trial NCT00258856 evaluated antibody persistence in children who had previously received one dose of Menactra or Menomune, linking the vaccine candidate to the Menactra name.